Model 1b分析性能规范——2025年布拉格研讨会报告
本报告汇总2025年布拉格研讨会的专家报告,会议专门聚焦基于Model 1b的分析性能规范(APS)。APS用于验证体外诊断医疗器械符合监管与质量标准、外部质量保证评估、质量控制与试剂批间变异监测、允许分析前变异评估,以及指导采购与报销决策。报告还提及Model 3通过外部质量保证评估现状、Model 2依赖生物学变异数据并由欧洲临床化学与实验室医学联合会数据库支持,但不同测量物与场景下最优APS设定方法仍存争议。
要点
- APS的核心目的是确保检测性能与特定临床目标一致。
- APS可用于IVD上市前验证、EQA、QC、试剂批间变异监测和采购决策。
- 2025年布拉格研讨会专门聚焦基于Model 1b的APS。
核心结论
- 2025年布拉格研讨会专门聚焦基于Model 1b的分析性能规范,报告汇总了相关专家报告。
研究设计与样本
- 本报告为2023年和2025年布拉格研讨会的会议报告,2025年会议专门聚焦基于Model 1b的APS。
主要发现
- APS可用于验证IVD医疗器械符合监管与质量标准、外部质量保证评估、质量控制、监测试剂批间变异、允许分析前变异评估以及指导采购与报销决策。
- Model 3通过外部质量保证评估IVD医疗器械的现状,不同国家和国际EQA提供者常采用不同的接受标准。
- Model 2依赖生物学变异数据,由欧洲临床化学与实验室医学联合会数据库及其交互工具支持计算APS。
- 关于最优APS设定方法及不同测量物和场景下最合适模型的争论仍在继续。
临床怎么用
- 检验科可依据APS验证IVD医疗器械、开展外部质量保证评估、实施质量控制与试剂批间变异监测,并评估分析前变异。
- 医疗机构、报销机构和保险公司可参考APS指导采购决策。
局限性
- 关于最优APS设定方法及不同测量物和场景下最合适模型仍存在争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The main purpose of establishing APS is to ensure that test performance aligns with their specific clinical goals. Analytical performance specifications serve multiple functions: as acceptance criteria to verify that in vitro diagnostic medical devices (IVD MD) meet regulatory and quality standards before market release; for external quality assurance assessments; for quality control, monitoring reagent lot-to-lot variability, and allowing preanalytical variation assessments in labs; and for guiding purchasing decisions by healthcare providers, reimbursement agencies, and both public and private insurers. Over the years, various systems and projects have been established to evaluate the current state of the art (Model 3) of IVD MD through external quality assurance (EQA). Different national and international EQA providers often use distinct acceptance criteria tailored to their organisational goals and local healthcare settings. Model 2, which relies on biological variation data, has been effectively supported by the European Federation of Clinical Chemistry and Laboratory Medicine's database and its interactive tools for calculating APS (www.biologicalvariation.eu). Nonetheless, debates continue about optimal APS setting methods and the most suitable models for different measurands and scenarios. To explore these issues further, workshops were held in Prague in 2023 and 2025. This report presents the expert presentations from the 2025 workshop, which exclusively focused on APS based on Model 1b.
引用
- Horvath AR, Sandberg S, Thelen MHM, et al. Model 1b analytical performance specifications - report on the Prague 2025 workshop. Clin Chem Lab Med. 2026. PMID: 42605217. doi:10.1515/cclm-2026-1024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。